SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-24-000145
Filing Date
2024-06-21
Accepted
2024-06-21 17:11:02
Documents
3
Period of Report
2024-06-21

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1719004255.html 4  
1 FORM 4 wk-form4_1719004255.xml 4 3587
2 EX-24 pagesfromzntl-powerofatt.htm EX-24 4083
3 pagesfromzntl-powerofatt001.jpg GRAPHIC 250533
  Complete submission text file 0001725160-24-000145.txt   354520
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address
Skvarka Jan (Reporting) CIK: 0001838042 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 241061343